"Leiomyosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A sarcoma containing large spindle cells of smooth muscle. Although it rarely occurs in soft tissue, it is common in the viscera. It is the most common soft tissue sarcoma of the gastrointestinal tract and uterus. The median age of patients is 60 years. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p1865)
| Descriptor ID |
D007890
|
| MeSH Number(s) |
C04.557.450.590.455 C04.557.450.795.455
|
| Concept/Terms |
Leiomyosarcoma, Epithelioid- Leiomyosarcoma, Epithelioid
- Epithelioid Leiomyosarcoma
- Epithelioid Leiomyosarcomas
- Leiomyosarcomas, Epithelioid
Leiomyosarcoma, Myxoid- Leiomyosarcoma, Myxoid
- Leiomyosarcomas, Myxoid
- Myxoid Leiomyosarcoma
- Myxoid Leiomyosarcomas
|
Below are MeSH descriptors whose meaning is more general than "Leiomyosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Leiomyosarcoma".
This graph shows the total number of publications written about "Leiomyosarcoma" by people in this website by year, and whether "Leiomyosarcoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leiomyosarcoma" by people in Profiles.
-
Survival analyses of soft tissue pleomorphic sarcomas and a proposed leiomyosarcoma-specific dynamic nomogram: A large population-based study. Pathol Res Pract. 2022 Sep; 237:153999.
-
HPV51-associated Leiomyosarcoma: A Novel Class of TP53/RB1-Wildtype Tumor With Predilection for the Female Lower Reproductive Tract. Am J Surg Pathol. 2022 06 01; 46(6):729-741.
-
Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer?-accredited facilities. Gynecol Oncol. 2020 04; 157(1):121-130.
-
Orbital leiomyosarcoma metastasis presenting prior to diagnosis of the primary tumor. Digit J Ophthalmol. 2017; 23(4):22-26.
-
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study. J Clin Oncol. 2015 Apr 01; 33(10):1180-5.
-
A Phase II evaluation of ixabepilone (IND #59699, NSC #710428) in the treatment of recurrent or persistent leiomyosarcoma of the uterus: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2014 Oct; 135(1):44-8.
-
A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study. Gynecol Oncol. 2012 Jan; 124(1):48-52.
-
Renal smooth muscle hamartoma. Pathol Res Pract. 2010 Nov 15; 206(11):782-4.
-
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008 Jun; 109(3):329-34.
-
A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study. Gynecol Oncol. 2007 Sep; 106(3):596-603.